Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07277322 | Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases | PHASE1 | NOT YET_RECRUITING | 24 | — | — | Jun 1, 2026 | Dec 31, 2030 | Apr 29, 2026 | 1 | United States |
Phase 2: Safety of treatment, defined as the frequency and percentage of DLTs, from start of treatment up to 30 days post the last administration of study drug (dupilumab).
| Arm | Type | Description |
|---|---|---|
| Dupilumab and toripalimab | EXPERIMENTAL | Participants will receive the combination of Dupilumab and Toripalimab |
| Name | Type | Description |
|---|---|---|
| Dupilumab | DRUG | Dupilumab is commercially sourced, and provided as 300mg pre-filled syringes, though packaging may vary. Dupilumab 600mg SC on Day 1 and 300mg SC on Day 15 (+/-2 days). |
| Toripalimab | DRUG | Toripalimab will be supplied as a liquid in sterile, single-use vials that will display the product lot number on the label. Each vial contains 240 mg/6 mL (40 mg/mL) solution. Toripalimab 240mg IV over 60 minutes or longer on Day 1 before planned surgery. |
INCLUSION CRITERIA: Histological diagnosis of non-MSI-H/pMMR CRC • Subjects who have biology-proven non-MSI-H/pMMR CRC and with radiographic findings suggestive of liver metastases may be eligible. Resectable liver metastases including: * synchronous liver metastases (present at the time of diag...